[Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
Tedeholm
Helen
H
Göteborgs universitet.
Skoog
Bengt
B
Hillert
Jan
J
Runmarker
Björn
B
Stawiarz
Leszek
L
Oluf
Andersen
A
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D015331:Cohort Studies; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000627:therapeutic use*; D010919:Placebos; D011379:Prognosis; D012042:Registries; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D010455:Peptides; D010919:Placebos; D000068717:Glatiramer Acetate; D016899:Interferon-beta